Actelion Ltd. Soars As Heart-Lung Drug Selexipag Meets Main Goal In Late-Stage Study

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - Actelion Ltd said its experimental heart and lung drug Selexipag met its primary goal in a late-stage study, giving the Swiss biotech company a potential second big seller to replenish its product pipeline.

Selexipag is the third drug from Actelion to treat pulmonary arterial hypertension (PAH), a progressively worsening condition characterised by abnormally high blood pressure in the arteries of the lungs. The cause is unknown and the disease has no cure. The positive result is a boost to Europe's biggest biotech company and should reassure investors that the firm's long-term growth prospects are on course, after another PAH treatment, Opsumit, won approval in Europe and the United States.

Help employers find you! Check out all the jobs and post your resume.

Back to news